Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT07545811
Phase
PHASE1
Sponsor
Janux Therapeutics
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • JANX014
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Charleston, South Carolina, United States|32.77632,-79.93275
  • Greenville, South Carolina, United States|34.85262,-82.39401
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Male ≥18 years of age at the time of signing informed consent
  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Partic…
  • Adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →